SUPERIOR, SUSTAINED PAIN RELIEF.

DTM™ SCS compared to conventional stimulation at 12 months in an RCT.

Setting a new benchmark for SCS Outcomes

84%

Highest back pain responder rate reported at 12 months in similar RCTs* *(> 50% improvement[1]).*



** Descriptive comparison, including studies with similar design (RCT; randomization >100 subjects; comparing 2 SCS therapies; with at least 12-months follow up) and patient populations (inclusion/exclusion criteria; baseline demographics) with back pain responder rates reported. This is not based on a statistical analysis of outcomes between studies.*



7 out of 10

experienced **profound back pain relief**[1] *(≥ 80% pain relief)*

83%

of patients were **satisfied/ very satisfied** at 12 months[2]



1. Fishman M, Cordner H, Justiz R, et al. Randomized Controlled Clinical Trial to Study the Effects of Differential Target Multiplexed™ SCS (DTM™ SCS) in Treating Intractable Chronic Low Back Pain: Long-term Follow-Up Results. Presented at: North American Neuromodulation Society 24th Annual Meeting. Jan 15–16, 2021. Virtual.
2. Vallejo R, Fishman M, Cordner H, et al. Differential Target Multiplexed™ SCS (DTM™ SCS) for Treating Intractable Chronic Low Back and Leg Pain: Profound Response and Long-Term Benefits in Quality of Life. Presented at: North American Neuromodulation Society 24th Annual Meeting. Jan 15–16, 2021. Virtual.

Medtronic
Further, Together